It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...

Two AS01-adjuvanted vaccines for different pathogens -- the respiratory syncytial virus (RSV) vaccine (Arexvy) and the ...

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

Some vaccines may reduce the risk of dementia through a double effect in which the jabs help protect the brain through their ...

A new study shows that a vaccine against respiratory syncytial virus is associated with a 29% reduction in dementia risk in ...

Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult ...

Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

New research suggests vaccines against "potentially serious and life-threatening infections" could offer double protection ...

A study published in NPJ Vaccines looks at adjuvants in vaccines and their association with a lower risk of dementia. Dr Julia Dudley, Head of Research at Alzheimer’s Research UK, said: ...

GSK plc has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted the company's regulatory ...

(Alliance News) - GSK PLC on Friday announced that Japan has accepted a regulatory application to expand the use of its respiratory syncytial virus [RSV] vaccine Arexvy.